Most common barriers encountered relating to individualizing antihyperglycemic agents are costs of the medications for the patients and fear of needles when GLP1 agonists or insulins are recommended.
Demonstrating the ease with which these medications are delivered with demo devices helps patients accept them and feel confident using the devices.